FAM57B is a modulator of ceramide synthesis that regulates sphingolipid homeostasis and synaptic composition in the developing brain

The complex 16p11.2 Deletion Syndrome (16pdel) is accompanied by neurological disorders, including epilepsy, autism spectrum disorder and intellectual disability. We demonstrate that 16pdel iPSC differentiated neurons showed augmented local field potential activity and altered ceramide-related lipid species relative to unaffected. FAM57B, a poorly characterized gene in the 16p11.2 interval, has emerged as a candidate tied to symptomatology. We found that FAM57B modulates ceramide synthase (CerS) activity, but is not a CerS per se. In FAM57B mutant human neuronal cells and zebrafish brain, composition and levels of sphingolipids and glycerolipids associated with cellular membranes are disrupted. Consistently, we observed aberrant plasma membrane architecture and synaptic protein mislocalization, which were accompanied by depressed brain and behavioral activity. Together, these results suggest that haploinsufficiency of FAM57B contributes to changes in neuronal activity and function in 16pdel Syndrome, through a crucial role for the gene in lipid metabolism.

[1]  L. D. Costa,et al.  Vascular contributions to 16p11.2 deletion autism syndrome modeled in mice , 2020, Nature Neuroscience.

[2]  So Hyun Kim,et al.  Language characterization in 16p11.2 deletion and duplication syndromes. , 2020, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[3]  L. Henneman,et al.  Who ever heard of 16p11.2 deletion syndrome? Parents’ perspectives on a susceptibility copy number variation syndrome , 2020, European Journal of Human Genetics.

[4]  B. Poll-The,et al.  Hyperinsulinism in a patient with a Zellweger Spectrum Disorder and a 16p11.2 deletion syndrome , 2020, Molecular Genetics and Metabolism Reports.

[5]  W. Chung,et al.  Sensorimotor Cortical Oscillations during Movement Preparation in 16p11.2 Deletion Carriers , 2019, The Journal of Neuroscience.

[6]  Jared A. Nielsen,et al.  Quantifying the Effects of 16p11.2 Copy Number Variants on Brain Structure: A Multisite Genetic-First Study , 2018, Biological Psychiatry.

[7]  R. Kuzniecky,et al.  Focal Cortical Anomalies and Language Impairment in 16p11.2 Deletion and Duplication Syndrome , 2018, Cerebral cortex.

[8]  H. Sive,et al.  The 16p11.2 homologs fam57ba and doc2a generate certain brain and body phenotypes , 2017, Human molecular genetics.

[9]  Yuichiro Watanabe,et al.  Novel Rare Missense Variations and Risk of Autism Spectrum Disorder: Whole-Exome Sequencing in Two Families with Affected Siblings and a Two-Stage Follow-Up Study in a Japanese Population , 2015, PloS one.

[10]  J. Sebat,et al.  Spatiotemporal 16p11.2 Protein Network Implicates Cortical Late Mid-Fetal Brain Development and KCTD13-Cul3-RhoA Pathway in Psychiatric Diseases , 2015, Neuron.

[11]  N Hadjikhani,et al.  The 16p11.2 locus modulates brain structures common to autism, schizophrenia and obesity , 2014, Molecular Psychiatry.

[12]  Abraham Z. Snyder,et al.  Opposing Brain Differences in 16p11.2 Deletion and Duplication Carriers , 2014, The Journal of Neuroscience.

[13]  P. Striano,et al.  Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy , 2014, Annals of neurology.

[14]  Y. Okazaki,et al.  Fam57b (Family with Sequence Similarity 57, Member B), a Novel Peroxisome Proliferator-activated Receptor γ Target Gene That Regulates Adipogenesis through Ceramide Synthesis* , 2012, The Journal of Biological Chemistry.

[15]  Allison G. Dempsey,et al.  A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disorders , 2012, Journal of Medical Genetics.

[16]  The Simons,et al.  Simons Variation in Individuals Project (Simons VIP): A Genetics-First Approach to Studying Autism Spectrum and Related Neurodevelopmental Disorders , 2012, Neuron.

[17]  Gary D Bader,et al.  Functional impact of global rare copy number variation in autism spectrum disorders , 2010, Nature.

[18]  Kenny Q. Ye,et al.  Strong Association of De Novo Copy Number Mutations with Autism , 2007, Science.

[19]  S. Ben-Dor,et al.  When Do Lasses (Longevity Assurance Genes) Become CerS (Ceramide Synthases)? , 2006, Journal of Biological Chemistry.

[20]  L. Pike Lipid rafts Published, JLR Papers in Press, February 1, 2003. DOI 10.1194/jlr.R200021-JLR200 , 2003, Journal of Lipid Research.

[21]  A. Chapelle,et al.  The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8 , 1999, Nature Genetics.

[22]  Gerd Geisslinger,et al.  Chain length-specific properties of ceramides. , 2012, Progress in lipid research.